Curis, Inc.

Healthcare · Biotechnology · United States

Last price 0.6 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.46M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refra...